Clinical Trials

Find trials

Perform a New Search

Search Results 1-10 of 27 for

Results filtered:
Study status: Open/Status Unknown

Edit search filters

MC230813 A Study Of Golcadomide With Rituximab Prior To CAR-T With Relapsed Or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)

Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

See Details

MC230813 A Study Of Golcadomide With Rituximab Prior To CAR-T With Relapsed Or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to evaluate efficacy as measured by the disease control rate (CMR, PMR, and NMR) by Lugano 2014 PET-CT based assessment after 2 cycles of therapy.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
La Crosse, Wis.	Open for enrollment	View complete study & contact information
Mankato, Minn.	Open for enrollment
Rochester, Minn.	Open for enrollment
Eau Claire, Wis.	Open for enrollment
Jacksonville, Fla.	Open for enrollment
Albert Lea, Minn.	Open for enrollment
Scottsdale/Phoenix, Ariz.	Open for enrollment

Print study details

Site IRB:
- La Crosse, Wisconsin: 24-005122
- Mankato, Minnesota: 24-005122
- Rochester, Minnesota: 24-005122
- Eau Claire, Wisconsin: 24-005122
- Jacksonville, Florida: 24-005122
- Albert Lea, Minnesota: 24-005122
- Scottsdale/Phoenix, Arizona: 24-005122
NCT ID:
NCT06834373
Sponsor Protocol Number:
MC230813

CD19-Directed CAR-T Cell Therapy For The Treatment Of Relapsed/Refractory B Cell Malignancies

Rochester, MN
- See Details
CD19-Directed CAR-T Cell Therapy For The Treatment Of Relapsed/Refractory B Cell Malignancies
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  1
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

The purpose of this study is to find out more about the side effects of the CAR-T therapy called IC19/1563 and what dose of IC19/1563 is safe for patients.

The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill cancer cells. In this study, some of the patient's T cells will be removed from their blood. In the laboratory, we will put a new gene into the T cells. This gene allows the T cells to recognize and possibly treat the cancer. The new modified T cells are called the IC19/1563 treatment. The dose of IC19/1563 will depend on when the patient is enrolled on to the study.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Contact us for the latest status
View complete study & contact information

Print study details
Site IRB:
Rochester, Minnesota: 20-007714

NCT ID:
NCT04892277

Sponsor Protocol Number:
MC198A
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy In Adults With CD33 And/or FLT3 Blood Cancers Including AML/MDS

Jacksonville, FL
- See Details
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy In Adults With CD33 And/or FLT3 Blood Cancers Including AML/MDS
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  1
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Contact us for the latest status
View complete study & contact information

Print study details
Site IRB:
Jacksonville, Florida: 24-005775

NCT ID:
NCT06325748

Sponsor Protocol Number:
SENTI-202-101

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Contact us for the latest status	View complete study & contact information

Mayo Clinic Location	Status	Contact
Jacksonville, Fla.	Contact us for the latest status	View complete study & contact information

GPRC5D-directed CAR T Cell Therapy In Participants With Relapsed Or Refractory Multiple Myeloma

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

GPRC5D-directed CAR T Cell Therapy In Participants With Relapsed Or Refractory Multiple Myeloma

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to evaluate the efficacy of BMS-986393 in participants with quadruple class exposed R/R MM having received at least 4 prior LOT.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Open for enrollment	View complete study & contact information
Scottsdale/Phoenix, Ariz.	Closed for enrollment
Jacksonville, Fla.	Open for enrollment

Print study details

Site IRB:
- Rochester, Minnesota: 24-012405
- Scottsdale/Phoenix, Arizona: 24-012405
- Jacksonville, Florida: 24-012405
NCT ID:
NCT06297226
Sponsor Protocol Number:
CA0881000

Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Jacksonville, FL, Rochester, MN
- See Details
Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
About this study

The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Open for enrollment
View complete study & contact information

Rochester, Minn.

Open for enrollment

Print study details
Site IRB:
Jacksonville, Florida: 23-004847
Rochester, Minnesota: 23-004847

NCT ID:
NCT05776134

Sponsor Protocol Number:
KT-US-472-0141

MC230818 Understanding the mechanisms of clonal and non-clonal cytopenia following CAR-T therapy (MC230818)

Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

See Details

MC230818 Understanding the mechanisms of clonal and non-clonal cytopenia following CAR-T therapy (MC230818)

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

About this study

Determine the preexisting and therapy-emergent germline and somatic variants associated with an increased risk of clonal and non-clonal cytopenia following CAR-T cell therapy.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Mankato, Minn.	Open for enrollment	View complete study & contact information
Rochester, Minn.	Open for enrollment
La Crosse, Wis.	Open for enrollment
Jacksonville, Fla.	Open for enrollment
Eau Claire, Wis.	Open for enrollment
Scottsdale/Phoenix, Ariz.	Open for enrollment
Albert Lea, Minn.	Open for enrollment

Print study details

Site IRB:
- Mankato, Minnesota: 24-005734
- Rochester, Minnesota: 24-005734
- La Crosse, Wisconsin: 24-005734
- Jacksonville, Florida: 24-005734
- Eau Claire, Wisconsin: 24-005734
- Scottsdale/Phoenix, Arizona: 24-005734
- Albert Lea, Minnesota: 24-005734
NCT ID:
NCT06630104
Sponsor Protocol Number:
MC230818

Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Jacksonville, FL, Rochester, MN
- See Details
Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
About this study

The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Open for enrollment
View complete study & contact information

Rochester, Minn.

Open for enrollment

Print study details
Site IRB:
Jacksonville, Florida: 23-004786
Rochester, Minnesota: 23-004786

NCT ID:
NCT05776160

Sponsor Protocol Number:
KT-US-471-0140

A Study Of GC012F (AZD0120), A CAR T Therapy Targeting CD19 And BCMA In Subjects With Relapsed/Refractory Multiple Myeloma

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

A Study Of GC012F (AZD0120), A CAR T Therapy Targeting CD19 And BCMA In Subjects With Relapsed/Refractory Multiple Myeloma

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
1/2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Open for enrollment	View complete study & contact information
Scottsdale/Phoenix, Ariz.	Open for enrollment
Jacksonville, Fla.	Open for enrollment

Print study details

Site IRB:
- Rochester, Minnesota: 23-009717
- Scottsdale/Phoenix, Arizona: 23-009717
- Jacksonville, Florida: 23-009717
NCT ID:
NCT05850234
Sponsor Protocol Number:
D8310C00001

A Study To Evaluate The Safety, Effectiveness And Tolerable Dose Of Arlocabtagene Autoleucel (BMS-986393) In Novel Combinations In Participants With Relapsed And/or Refractory Multiple Myeloma

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

A Study To Evaluate The Safety, Effectiveness And Tolerable Dose Of Arlocabtagene Autoleucel (BMS-986393) In Novel Combinations In Participants With Relapsed And/or Refractory Multiple Myeloma

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
1
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla.	Open for enrollment	View complete study & contact information
Rochester, Minn.	Open for enrollment
Scottsdale/Phoenix, Ariz.	Open for enrollment

Print study details

Site IRB:
- Jacksonville, Florida: 24-004039
- Rochester, Minnesota: 24-004039
- Scottsdale/Phoenix, Arizona: 24-004039
NCT ID:
NCT06121843
Sponsor Protocol Number:
CA0881005

Dasatinib And Quercetin With CAR T Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

Rochester, MN
- See Details
Dasatinib And Quercetin With CAR T Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  2
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

This phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Quercetin is a compound found in plants that may prevent multiple myeloma from forming. Chemotherapy such as cyclophosphamide and fludarabine are given to help kill any remaining cancer cells in the body and to prepare the bone marrow for CAR-T therapy. Chimeric antigen receptor T-cell Therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving dasatinib and quercetin with cyclophosphamide, fludarabine and CAR-T cell therapy may kill more cancer cells in patients with relapsed or refractory multiple myeloma.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Open for enrollment
View complete study & contact information

Print study details
Site IRB:
Rochester, Minnesota: 24-002915

NCT ID:
NCT06940297

Sponsor Protocol Number:
MC240801

Pagination Clinical studies

Clinical Trials

Filter Results

Locations

Study status

Gender

Age

Study phase

Search Results 1-10 of 27 for

MC230813 A Study Of Golcadomide With Rituximab Prior To CAR-T With Relapsed Or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)

CD19-Directed CAR-T Cell Therapy For The Treatment Of Relapsed/Refractory B Cell Malignancies

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy In Adults With CD33 And/or FLT3 Blood Cancers Including AML/MDS

GPRC5D-directed CAR T Cell Therapy In Participants With Relapsed Or Refractory Multiple Myeloma

Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

MC230818 Understanding the mechanisms of clonal and non-clonal cytopenia following CAR-T therapy (MC230818)

Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

A Study Of GC012F (AZD0120), A CAR T Therapy Targeting CD19 And BCMA In Subjects With Relapsed/Refractory Multiple Myeloma

A Study To Evaluate The Safety, Effectiveness And Tolerable Dose Of Arlocabtagene Autoleucel (BMS-986393) In Novel Combinations In Participants With Relapsed And/or Refractory Multiple Myeloma

Dasatinib And Quercetin With CAR T Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

Mayo Clinic Footer

Legal Conditions and Terms

Advertising

Reprint Permissions